Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Miki, Murota"'
Autor:
Kunihiko Kanatsu, Yoshinori Takahashi, Tetsuya Sakaguchi, Dae-Shik Kim, Miki Murota, Mingde Shan, Kazuki Fukami, Wataru Itano, Kenji Kikuta, Hikaru Yoshimura, Toshiki Kurokawa, Yuko Nagayama, Rena Ishikawa, Ryo Dairiki, Zhi Zhou, Kristen Sanders, Jacob Stupalski, So Yasui, Diana Liu, Farid Benayoud, Hui Fang, Enxuan Jing, Makoto Ogo, Francis G. Fang, John Wang, Hyeong-wook Choi
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 36, Iss 1, Pp 102404- (2025)
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research. To realize chronic administration of ASO therapeuti
Externí odkaz:
https://doaj.org/article/48fa025010654763a422d4a52be32434
Autor:
Hideki Sakai, Takaoki Uchiumi, Manabu Murakami, Kiyoshi Oketani, Tomoyuki Suzuki, Noriaki Takeguchi, Miki Murota
Publikováno v:
British Journal of Pharmacology. 136:383-390
E3040 (6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole), is a novel dual inhibitor of 5-lipoxygenase (5-LOX) and thromboxane synthase (Tx synthase). Here, we examined the effects of E3040 sulphate, a sulphate conjugate of E3040,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da26d090914ab31d6689a6eae61d3bc0
https://doi.org/10.1038/sj.bjp.0704723
https://doi.org/10.1038/sj.bjp.0704723
Autor:
Hiroki Terauchi, Hiroshi Kato, Sou Yasui, Daisuke Iida, Masanobu Shinoda, Yoshikuni Tabata, Kotaro Kodama, Hitoshi Harada, Hiroko Kuramochi, Tetsuya Kawahara, Masato Ueda, Hideaki Fujisaki, Junichi Nagakawa, Kubota Atsuhiko, Miki Murota, Shuhei Miyazawa, Kazuo Hirota, Nobuhisa Watanabe
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 334(2)
We have investigated the pharmacology of sodium (R)-2-[4-(2,2-dimethyl-1,3-dioxan-5-yl) methoxy-3,5-dimethylpyridin-2-yl]methylsulfinyl-1H-benzimidazol (E3710), a new proton pump inhibitor (PPI), and its effect on gastric acid secretion. E3710 irreve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1b06d5f878b1b39eab24295f04c7ebd
https://pubmed.ncbi.nlm.nih.gov/20484556
https://pubmed.ncbi.nlm.nih.gov/20484556
We have shown previously that thromboxane A2 (TXA2), which may be released by the anti-tumour drug irinotecan and by platelet-activating factor (PAF), causes Cl- secretion in the isolated rat colon. In the present study, the involvement of TXA2 in ni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7af833ebf5b08744fed6a174367d417c
https://europepmc.org/articles/PMC2290489/
https://europepmc.org/articles/PMC2290489/
Autor:
Hideki, Sakai, Tomoyuki, Suzuki, Miki, Murota, Kiyoshi, Oketani, Takaoki, Uchiumi, Manabu, Murakami, Noriaki, Takeguchi
Publikováno v:
British journal of pharmacology. 136(3)
1. E3040 (6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole), is a novel dual inhibitor of 5-lipoxygenase (5-LOX) and thromboxane synthase (Tx synthase). Here, we examined the effects of E3040 sulphate, a sulphate conjugate of E30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a58a1660007b93c041b686792429e8cf
https://pubmed.ncbi.nlm.nih.gov/12023941
https://pubmed.ncbi.nlm.nih.gov/12023941